Investigation

Rep. Gil Cisneros Bought Boston Scientific Before a VA Implant Procurement Package Reached Armed Services

Boston Scientific entered spring 2026 with a precise Washington ask: faster federal purchasing for medical implants, prosthetics, and neuromodulation products. Rep. Gil Cisneros, a House Armed Services member, disclosed three BSX purchases during the same window.

Published June 15, 2026

Boston Scientific spinal cord stimulation product image — Boston Scientific spinal-cord-stimulation product image from the company image gallery. Source: Boston Scientific.

Official portrait of Rep. Gil Cisneros — Rep. Gil Cisneros official portrait. Source: Wikimedia Commons.

Disclosed BSX purchases

All listed at $1,001-$15,000.

Q1 lobbying

$642K

Boston Scientific named H.R. 6549.

Boston Scientific global headquarters in Marlborough, Massachusetts. Source: Boston Scientific.

VA prosthetic socket image — VA prosthetics image from a VA Puget Sound feature on a personalized 3D-printed prosthetic socket. Source: VA.gov.

Finding

The official PTR shows BSX purchases on May 11, May 19, and May 29. Boston Scientific's Q1 lobbying filing, posted before those trades, named H.R. 6549 and described VA/DOD report language for product-add cycles and single-purchase-order procurement.

H.R. 6549 had a House hearing on May 20, one day after the second purchase. On June 10, a veterans package that included the contracting bill was referred to Veterans' Affairs and Armed Services, where Cisneros sits. The package also carried spinal-cord neuromodulation and VA prosthetics ordering language.

Cisneros BSX disclosure

Date	Ticker	Transaction	Disclosed value
May 11, 2026	BSX	Purchase	$1,001-$15,000
May 19, 2026	BSX	Purchase	$1,001-$15,000
May 29, 2026	BSX	Purchase	$1,001-$15,000

Source: House PTR #20034713.

Sources: House PTR; Boston Scientific lobbying filing; H.R. 6549 actions; H.R. 9237.

•••

The Committee Door

Cisneros's official page lists House Armed Services and Small Business. On June 10, Congress.gov recorded H.R. 9237 as referred to Veterans' Affairs and Armed Services.

H.R. 9237 carried two product lanes close to Boston Scientific's business: VA ordering controls for prosthetic and rehabilitative items, and spinal-cord injury evaluations that include assistive technology, spinal-cord neuromodulation, and FDA-approved implantable spinal-cord stimulation systems.

Relevant H.R. 9237 language

Section	Mechanism	BSX surface
316	VA formulary and electronic ordering for prosthetic and rehabilitative items.	Product-add, ordering, and national contract visibility.
329	Annual VA evaluations for spinal-cord injury or disorder, including spinal-cord neuromodulation.	Boston Scientific sells spinal-cord-stimulation and neuromodulation products.

Sources: Congress.gov H.R. 9237; GovInfo text.

What Boston Scientific Was Asking For

Boston Scientific's Q1 2026 lobbying filing named H.R. 6549, the VA Contracting and Procurement Act. The filing described medical implant acquisition, surgical-procedure billing, VHA medical-technology access, prosthetics procurement, and non-opioid pain management.

The procurement request was specific: FY2027 VA/DOD report language for a transparent product-add cycle and a streamlined single-purchase-order mechanism.

Lobbying lane

Boston Scientific Q1 2026 filing

Bill named

H.R. 6549, the VA Contracting and Procurement Act.

Issue

VHA medical-technology access, medical surgery and prosthetics procurement, non-opioid pain management, and VA/DOD report language.

Mechanism

Transparent product-add cycle and streamlined single-purchase-order procurement.

Source: Boston Scientific Q1 2026 lobbying filing.

The May 20 Hearing

The House held a hearing on H.R. 6549 on May 20, one day after the second BSX purchase. The bill text covers prosthetic appliances, surgical implants, manufacturer catalog revisions, firm-fixed single purchase orders, duplicate-billing controls, and implantable devices.

The Procurement Prototype

DLA opportunity SPE2DE25R0007 shows a federal catalog path for Boston Scientific Neuromodulation procedural packages under DLA Troop Support.

The justification describes a Manufacturer Direct Program for automated ordering instead of manual open-market purchasing. The package model includes just-in-time surgery delivery, direct vendor delivery, consignment, implantable devices, instrumentation sets, and surgical accessories.

Federal purchasing channel

DLA manufacturer-direct channel for BSX Neuromodulation

Program

Manufacturer Direct Program through DLA Troop Support Electronic Catalog.

Product

Boston Scientific Neuromodulation procedural packages.

Structure

Five-year fixed-price IDIQ with economic price adjustment.

Ceiling

$14.38M maximum value over five years.

Source: SAM.gov opportunity SPE2DE25R0007.

The Money

Boston Scientific reported $5.203 billion of Q1 2026 net sales, or about $20.8 billion annualized. The confirmed DLA channel has a $14.38 million five-year maximum, about $2.88 million a year.

Replication changes the numbers. A wider federal channel built around manufacturer-direct catalogs, national ordering, fewer manual open-market purchases, and proprietary implant packages would change the scale.

Procurement-channel sensitivity

Scenario	Five-year revenue	Annual run rate	% of annualized Q1 sales
Signed DLA J&A maximum	$14.4M	$2.9M	0.014%
10x replicated channel	$143.8M	$28.8M	0.138%
50x replicated channel	$719.0M	$143.8M	0.691%
100x replicated channel	$1.44B	$287.6M	1.382%

Sensitivity cases only. Sources: Boston Scientific Q1 2026 earnings and SAM.gov J&A.

The Product Lane

Boston Scientific's 2025 annual report lists Neuromodulation products for chronic pain and neurological movement disorders, including spinal-cord stimulation and deep-brain stimulation systems. The Q1 2026 earnings release reported 17.4% growth in Neuromodulation.

FDA's PMA database lists a May 21, 2026 decision date for Boston Scientific's Celestia implantable pulse generator and external trial stimulator, with the generic device category described as a totally implanted spinal-cord stimulator for pain relief. The FDA page was last updated June 8; the usable public marker is the May 21 decision date.

Timeline

Date	Event
Apr. 20	Boston Scientific filed Q1 lobbying that named H.R. 6549 and VA/DOD procurement modernization.
Apr. 22	Boston Scientific reported Q1 2026 sales of $5.203B and 17.4% reported Neuromodulation growth.
May 5	USAspending shows a VA purchase order to Boston Scientific for PROSTHETICS - NEUROTRANSMITER.
May 8	USAspending shows a VA purchase order to Boston Scientific Neuromodulation for PROSTHETICS:IMPLANT.
May 11	Cisneros purchased BSX.
May 19	Cisneros purchased BSX again.
May 20	H.R. 6549 had a House committee hearing.
May 21	FDA PMA database lists a decision date for Boston Scientific's Celestia SCS supplement.
May 29	Cisneros purchased BSX a third time.
June 10	H.R. 9237 was referred to Veterans' Affairs and Armed Services; the House VA release listed H.R. 6549 among the package's contracting and procurement changes.

Source Index

House PTR #20034713: official source for the three BSX purchases.

Cisneros committee page: official source for committee assignments.

Boston Scientific Q1 lobbying filing: source for H.R. 6549 and VA/DOD procurement language.

H.R. 6549: official VA Contracting and Procurement Act record.

H.R. 9237: larger veterans package referred to Armed Services.

SAM.gov SPE2DE25R0007: manufacturer-direct BSX Neuromodulation channel.

USAspending May 5 VA order: prosthetics/neurotransmitter purchase-order row.

USAspending May 8 VA order: prosthetics/implant order to BSX Neuromodulation.

Politraders newsletter

Stay on track with new investigations.

Get congressional trade alerts, source-backed articles, and policy context when new public records drop.

Join the newsletter

This article is for public-record research and informational purposes only. It is not financial or legal advice. Congressional financial disclosures provide value ranges; trade intent is outside the filing.